Activated Clotting Time Platforms Matter: Evidence Gaps and Real-World Variability in Anticoagulation Targets During Left Atrial Ablation.

Background Activated clotting time (ACT) is used to guide intraprocedural heparin anticoagulation during left atrial ablation, with guideline-recommended target values generally assumed to be device-independent.Objective To assess whether measured ACT values differ across measurement platforms and whether contemporary anticoagulation strategies vary accordingly in clinical practice.Methods We performed a PRISMA-registered systematic review of studies directly comparing ACT values across different measurement platforms during left atrial ablation. In parallel, we conducted an international physician survey assessing ACT platforms, heparin dosing strategies and targeted ACT ranges.Results The systematic review identified four electrophysiology-specific studies comparing ACT platforms. Across all studies, simultaneously measured ACT values differed substantially between platforms, with mean paired differences of 50-60 seconds, corresponding to a 15-25% discrepancy at ACT targets of 300-350 s. These inter-platform differences persisted despite high correlation between devices. The survey was completed by 164 electrophysiologists (82% Europe, 13% North America). The most commonly used platforms were Hemochron (42%), Medtronic ACT Plus (27%), and Abbott i-STAT (16%). Target ACT ranges and heparin dosing strategies varied by platform: higher ACT targets and higher weight-based heparin doses were most frequently reported with Hemochron, lower targets and doses were more common with i-STAT; Medtronic users showed an intermediate pattern. Nearly one-third of respondents reported modifying heparin dosing after switching ACT platforms.Conclusion Available cross-validation data demonstrate substantial differences between ACT platforms. Real-world heparin administration strategies and ACT targets vary markedly by platform. These findings challenge the assumption of universal ACT targets and highlight the need for platform-specific interpretation.

Authors

Publication Details

Journal
Open Access CRIS of the University of Bern
Published
2026-03-07
DOI
https://doi.org/10.48620/96171
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Activated Clotting Time Platforms Matter: Evidence Gaps and Real-World Variability in Anticoagulation Targets During Left Atrial Ablation.

Stefan Stojković, Boldizsar Kovacs, Leon Dinshaw, Thomas Küffer et al.
Open Access CRIS of the University of Bern
Atrial Fibrillation Management and Outcomes
article

Activated Clotting Time Platforms Matter: Evidence Gaps and Real-World Variability in Anticoagulation Targets During Left Atrial Ablation.

Stefan Stojković, Boldizsar Kovacs, Leon Dinshaw, Thomas Küffer, Stefan Kurath-Koller, Nina L. Rohrbach, Bert Vandenberk, Doreen Schöppenthau, Tobias Reichlin, Stefan Simovic, Laurent Roten, Kevin Vernooy, Dominik Linz, Valon Spahiu
article en

Abstract

Background Activated clotting time (ACT) is used to guide intraprocedural heparin anticoagulation during left atrial ablation, with guideline-recommended target values generally assumed to be device-independent.Objective To assess whether measured ACT values differ across measurement platforms and whether contemporary anticoagulation strategies vary accordingly in clinical practice.Methods We performed a PRISMA-registered systematic review of studies directly comparing ACT values across different measurement platforms during left atrial ablation. In parallel, we conducted an international physician survey assessing ACT platforms, heparin dosing strategies and targeted ACT ranges.Results The systematic review identified four electrophysiology-specific studies comparing ACT platforms. Across all studies, simultaneously measured ACT values differed substantially between platforms, with mean paired differences of 50-60 seconds, corresponding to a 15-25% discrepancy at ACT targets of 300-350 s. These inter-platform differences persisted despite high correlation between devices. The survey was completed by 164 electrophysiologists (82% Europe, 13% North America). The most commonly used platforms were Hemochron (42%), Medtronic ACT Plus (27%), and Abbott i-STAT (16%). Target ACT ranges and heparin dosing strategies varied by platform: higher ACT targets and higher weight-based heparin doses were most frequently reported with Hemochron, lower targets and doses were more common with i-STAT; Medtronic users showed an intermediate pattern. Nearly one-third of respondents reported modifying heparin dosing after switching ACT platforms.Conclusion Available cross-validation data demonstrate substantial differences between ACT platforms. Real-world heparin administration strategies and ACT targets vary markedly by platform. These findings challenge the assumption of universal ACT targets and highlight the need for platform-specific interpretation.

Open Access CRIS of the University of Bern
Openalex Percentile: Top 28%
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.